Can The NHS Survive?

[ad_1]

If you would like this piece read to you, just click above

Can the NHS survive? This is one thing that has been on my mind for many years, but particularly since covid. We can all argue about why we are in this position, but we are! It will be a close run thing, if we can bring our NHS back from where we are today. Personally I believe that it is political will, to destroy it. Otherwise why would there be such little concern for the service and it’s staff? Healthcare in the UK may be so problematic, that it is now too expensive for the public purse? Below I have laid out some of the issues to be urgently considered.

Introduction:

The National Health Service (NHS) has long been a symbol of pride for the United Kingdom, providing healthcare services to its citizens since its inception in 1948. However, in recent years, concerns about the sustainability and future of the NHS have emerged. In this blog post, we will delve into the challenges, and potential solutions facing the NHS. Analysing whether it will be able to survive and continue serving the needs of the UK population.

Rising Demand and Funding Pressures

The NHS faces the constant challenge of rising demand for healthcare services, due to various factors such as an aging population, increasing prevalence of chronic diseases, and advancements in medical treatments. This surge in demand, puts immense pressure on the NHS, exacerbating funding constraints, and stretching resources thin. To ensure the NHS’s survival, it is crucial to address these challenges, through long-term funding commitments, innovative financing models, and proactive health promotion strategies.

The aging population in the UK has led to a significant increase in the number of individuals requiring healthcare services. As people live longer, they tend to develop more complex conditions, leading to higher demand for specialized care. Additionally, the rising prevalence of chronic diseases further burdens the NHS as these require ongoing management.

Technological Advancements and Digital Transformation

Clinical technology

Moreover, constant advancements in medical treatments and technologies, have expanded healthcare possibilities. But often come with a hefty price tag. New medications, equipment, and procedures contribute to rising healthcare costs. The NHS must balance, providing the latest treatments, whilst managing its finances effectively.

While technology presents opportunities, through digitization and automation, to streamline processes and improve patient care. Implementing these, requires substantial investment, robust cybersecurity, and comprehensive training for healthcare professionals. Efforts should ensure vulnerable populations are not left behind, during the NHS’s digital transformation.

Workforce Crisis and Staffing Shortages

The NHS has been grappling with a workforce crisis. With shortages of healthcare professionals partly due to increasing workloads, burnout, and limited funding for training and recruitment. Addressing these challenges by targeting recruitment, improving retention strategies, and investing in professional development is vital to secure the NHS’s survival.

The demanding nature of healthcare work, has led to increased burnout and high turnover rates, making it difficult to retain experienced staff. Moreover, limited funding for training and recruitment, exacerbates this problem. Investing in workforce programs, improving working conditions, and providing adequate support systems can contribute to a more resilient workforce.

Political Will and Public Support

Steve Barclay talking to NHS staff and patient

The survival of the NHS, is linked to political will and public support. Policymakers must prioritize healthcare in their agendas, and allocate sufficient resources to ensure the NHS’s sustainability. Fostering public awareness and support can also drive necessary policy changes.

Maintaining public support requires transparent communication, about the complexities of funding and resources. By making healthcare a priority, policymakers can enact policies supporting the NHS’s long-term sustainability through strategic investments.

Potential Solutions for a Sustainable Future

To ensure the NHS’s survival, a long-term funding commitment is needed, to meet rising demand. Exploring financing models, like public-private partnerships can help bridge funding gaps. Investing in preventive care and public health initiatives can also alleviate the burden by reducing the need for costly interventions.

Embracing technology advancements and digitization, can enhance efficiency and effectiveness. Targeted recruitment, improved retention strategies, and professional development investment are essential to address the workforce crisis.

Conclusion

While the NHS faces numerous challenges, viable solutions of long-term funding, technology adoption, workforce strategies, and political support can pave the way for a sustainable future. We must recognize the NHS’s importance, and work towards its preservation, ensuring accessible, high-quality care for generations.

Our NHS has gone backwards in at least the last 10 years. Therefore, even if we can save it, we won’t again have a service we can be proud of, for possibly 20 years, if you include sorting out it’s decaying infrastructure too. The policy that we have seen, has not saved our country money, but cost it so much! Both financially, and the welfare of our people. We are now more reliant on big pharma than we were. Was that the plan all along? If you think that inequality is bad now, don’t even give any thought to private healthcare!

As always these are my personal thoughts and opinions based on my experiences. Please feel free to share your own below.

The post Can The NHS Survive? appeared first on Chris's cancer Community.

[ad_2]

Source link

Effects of Precision Medicine



Precision medicine has had a profound impact on cancer research and treatment.

Genetic Profiling: Precision medicine involves analyzing the genetic makeup of a patient’s tumor to identify specific mutations or alterations that drive cancer growth. This information helps oncologists select targeted therapies designed to address these specific genomic abnormalities.

Targeted Therapies: Targeted therapies are drugs that selectively attack cancer cells based on specific molecular characteristics. Precision medicine has led to the development of numerous targeted therapies, which often have fewer side effects compared to traditional chemotherapy because they spare healthy cells.

Companion Diagnostics: As precision medicine has advanced, so has the development of companion diagnostics. These are tests that identify patients who are most likely to respond positively to a particular targeted therapy, ensuring that treatment resources are used more effectively.

Treatment Resistance Management: Resistance to cancer treatments is a significant challenge. Precision medicine allows for the identification of resistance mechanisms, enabling healthcare providers to adapt treatment strategies and overcome resistance when it occurs.

Early Detection and Risk Assessment: Precision medicine has facilitated the identification of genetic markers associated with increased cancer risk. This enables early detection and risk assessment for individuals with a familial history of cancer, leading to timely interventions and improved outcomes.

Liquid Biopsies: Liquid biopsies are a non-invasive alternative to traditional tissue biopsies. These tests analyze circulating tumor DNA or other biomarkers in the blood to monitor treatment response, detect disease recurrence, and provide real-time insights into the tumor’s genetic profile.

Immunotherapy Advancements: Immunotherapy, which harnesses the body’s immune system to fight cancer, has seen significant advancements due to precision medicine. Identifying predictive biomarkers allows for better patient selection for immunotherapies, leading to improved responses.

Clinical Trial Design: Precision medicine has transformed the way clinical trials are designed and conducted. Trials can now be focused on specific patient populations with particular genetic profiles, making the development of new therapies more efficient.

Integration of Data and AI: The wealth of genomic and clinical data generated by precision medicine has led to the integration of artificial intelligence (AI) and machine learning in cancer research. AI helps analyze complex datasets and identify patterns that may lead to new therapeutic discoveries.

Challenges and Future Directions: Despite its successes, precision medicine in cancer still faces challenges, such as tumor heterogeneity, data-sharing, and cost considerations. Researchers continue to work on expanding precision medicine approaches to more cancer types and optimizing treatment strategies.

More information – https://oncologyandcancerresearch.blogspot.com/

International Conference on Oncology and Cancer Research:- https://oncology.pencis.com/
Award Nomination link: https://x-i.me/oan
Abstract Submission link: https://x-i.me/srimonco

For Inquiries: oncology@pencis.com

#shorts #shortsvideo #breastcancer #prostatecancer #lungcancer #coloncancer #ovariancancer #pancreaticcancer #leukemia #lymphoma #OncologyConference #CancerResearch #OncologyAwards #CancerTreatment #OncologyCommunity #CancerCare #OncologyEducation #CancerSurvivorship #OncologyInnovation #CancerAwareness #OncologyLeadership #CancerPrevention #fucancer #pediatriccancer #cancerawareness #beatcancer #cancersucks #cancerresearch #cancerfighter #cancerwarrior #cancertreatment #cancersurvivor #cancerprevention #cancerawarenessmonth #cancerpatientsupport #breastcancer #prostatecancer #lungcancer #coloncancer #ovariancancer #pancreaticcancer #leukemia #lymphoma #melanoma #braincancer #childhoodcancer #cancerfree #oncology #cancercare #cancerdiagnosis #cancerribbon #cancerjourney

CONNECT HERE:-

Facebook : https://www.facebook.com/Conference-101261931798599
twitter :https://twitter.com/Samirabellil
pinterest : https://in.pinterest.com/OncologyandCancerResearch/
Blog :https://oncologyandcancerresearch.blogspot.com/
tumblr :https://www.tumblr.com/blog/view/cancer-researcher
instagram :https://www.instagram.com/oncology_researcher/
linkedin : https://www.linkedin.com/in/cathenna-malia-a20834219/

source

Using Technology to Find Cancers Early and Exercise Improves Sexual Health for People With Prostate Cancer: Research from the 2023 ASCO Breakthrough Meeting

[ad_1]

The 2023 American Society of Clinical oncology (ASCO) Breakthrough meeting will be held in person and online August 3 to 5 in Yokohama, Japan. This meeting shines a light on the cutting-edge advances that are transforming cancer care in Asia and beyond. Research highlighted at ASCO Breakthrough will explore how new technologies may intersect with clinical care today to improve patients’ lives and well-being.

You can learn more about research from this meeting by following the #ASCOBT23 hashtag on Twitter.

Below are summaries of 4 studies that will be presented at the meeting:

Stool DNA test accurately detects gastrointestinal cancers and identifies tumor location

Who does this study affect: People at risk for gastrointestinal cancers.

What did this study find: A study out of China found that a new, noninvasive multi-target stool DNA test was able to accurately detect gastrointestinal (GI) cancers and identify the location where the cancer started.

GI cancers are cancers that affect the body’s GI tract, which is the bodily system involved in swallowing and digesting food, absorbing nutrients, and removing waste from the body. These cancers include cancer.net/cancer-types/bile-duct-cancer-cholangiocarcinoma”>bile duct cancer, colorectal cancer, esophageal cancer, pancreatic cancer, and stomach cancer, among others. Overall, GI cancers make up one-fourth of cancer cases around the world, according to the World Health Organization.

While tests using either stool (feces) or Blood have been approved by the U.S. Food and Drug Administration for the early detection of colorectal cancer, there are currently no similar tests approved for the early detection of other GI cancers. Stool tests are noninvasive, and most people can do the test at home. In this study, researchers wanted to learn whether using a new stool DNA test could detect and locate more GI cancers early.

The study included 124 Chinese people who had been diagnosed with GI cancer but had not received treatment, as well as 92 people who did not have cancer but received GI cancer-related examinations every 3 years.

The study showed that the test was able to accurately detect GI cancers and identify the location where the cancer started. Overall, of the patients who had cancer, 79% tested positive for cancer with the test, and of the patients who did not have cancer, 96% tested negative for cancer. Of the 4 participants who did not have cancer but received a positive result from the test, 3 were diagnosed with advanced adenomas, which are benign tumors that can become cancerous, and 1 person was pregnant.

For each of the specific GI cancer types included in the study, the test positively identified 71% of colorectal cancer cases, 83% of stomach cancer cases, 75% of esophageal cancer cases, 81% of pancreatic cancer cases, and 91% of ampullary cancer cases. Ampullary cancer is cancer of the ampulla of Vater, which is where the pancreatic duct and bile duct meet and empty into the first part of the small intestine.

The researchers also evaluated how effective the test was in identifying the type of GI cancer, which is called sensitivity. Sensitivity is the percentage of people with cancer who were correctly identified by the test as having cancer. The sensitivity of the test was 88% for colorectal cancer, 91% for stomach cancer, 88% for esophageal cancer, 90% for pancreatic cancer, and 95% for ampullary cancer.

What does this mean for patients: This noninvasive stool DNA test could help detect different GI cancers early and accurately, including the location where the cancer started.

Stool is a promising sample for GI cancer detection because it contains the host’s exfoliated cells and circulating-free DNA derived from GI cancer cells. Our study aims to develop a noninvasive, multi-target stool DNA methylation test for the early detection and localization of GI cancers.”

—      lead study author Li-Yue Sun, MD
Guangdong Second Provincial General Hospital
Guangzhou, China

Exercise helps improve sexual health for people with prostate cancer 

Who does this study affect: People with cancer.net/cancer-t%C3%BDpes/prostate-cancer“>prostate cancer.

What did this study find: Results from a randomized, controlled clinical trial from Australia found that patients who followed a supervised exercise program had improved sexual health. Prostate cancer and its treatment can lead to problems with sexual health, including erectile dysfunction and a loss of sexual desire. These sexual side effects may be temporary, but some can last for a long time. Side effects that change sexual health can affect a person mentally, emotionally, and physically.

In this study, the researchers wanted to see whether supervised resistance and aerobic exercise given in the clinic would improve sexual health. Aerobic exercise is also known as cardio, and it is the type of exercise that raises your heart rate. Resistance exercise is also called strength training. The researchers also wanted to explore whether adding a type of counseling called psychosexual therapy would help.

The study included 112 men with prostate cancer who had or were receiving cancer treatment and who had concerns about problems with sexual health. This study was done at exercise clinics that were connected to universities between 2014 and 2018. The participants were divided into 3 study groups. Group 1 included 39 people who received 6 months of supervised resistance and aerobic exercise in a group setting for 3 days per week. The 36 patients in Group 2 received the same exercise program plus psychosexual therapy. The 37 patients in Group 3 received usual care for prostate cancer, which does not include supervised exercise instruction.

The researchers evaluated whether the participants in Groups 1 and 2 were more satisfied with their sexual function than those in Group 3. To do this, participants were asked to complete a questionnaire called the International Index of Erectile Function (IIEF), which scores a person’s sexual ability and satisfaction with sexual activity. Those who participated in the supervised exercise program had a 5.1-point increase in their ability to have an erection of the penis compared with a 1.0-point increase in those who received usual care. Those who received supervised exercise also were more satisfied with sexual intercourse. Their satisfaction with sex increased by 2.2 points, compared with 0.2 points for those who received usual care. The psychosexual therapy, which was self-managed, did not add any improvements for the participants.

What does this mean for patients? Supervised resistance and aerobic exercise improved ability to have an erection and satisfaction with sexual intercourse for patients with prostate cancer.

Nearly half of patients with prostate cancer report having unmet sexual health care needs, highlighting the lack of current health care services to adequately address the demand for management of sexual dysfunction after prostate cancer treatment. Our study shows that these patients can immediately benefit from supervised exercise interventions to improve their sexual health and that exercise should be considered as an integral part of treatment for prostate cancer.”  

—lead study author Daniel Abido Galvao, PhD
Edith Cowan University
Perth, Australia 

Return to top

Artificial intelligence can accurately identify cervical precancerous lesions during colposcopy

Who does this study affect: People at increased risk for cancer.net/cancer-types/cervical-cancer“>cervical cancer.

What did this study find: A study out of Japan found that a new artificial intelligence (AI)-based model can accurately identify cervical intraepithelial neoplasia (CIN) lesions from videos taken during colposcopy. CIN, which may also be called cervical dysplasia, is an abnormal growth of cells on the cervix, which is part of the female reproductive system. While some of these abnormal cells may go away without treatment, others may eventually become cervical cancer.

A colposcopy is a procedure used to find cancerous or abnormal cells in the cervix, vagina, or vulva. A colposcopy may be recommended for people who received abnormal results following a Pap test so the doctor can confirm and diagnose certain problems, including CIN. During a colposcopy, the doctor may also perform a biopsy, which is the removal of a small amount of tissue for examination under a microscope, to determine whether abnormal areas found during the colposcopy may be cancerous or precancerous.

Extensive colposcopy training is required to teach doctors how to accurately detect CIN and perform more precise biopsies of suspicious areas. In this study, researchers wanted to learn whether an AI-based model could be used to accurately identify precancerous lesions from colposcopy results and help guide where biopsies should be performed.

Researchers conducted an analysis using 8,341 videos recorded during colposcopies from 2013 to 2019. The videos included 7 early-stage cervical cancer cases, 203 CIN3 cases, 276 CIN2 cases, and 456 CIN1 cases. CIN1 lesions have the lowest risk of becoming cancer, while CIN3 lesions have the highest risk of becoming cancer.

Researchers then trained the AI-based lesion detection model by showing it videos of 60 cases of cervical cancer and CIN3. The AI-based model was then shown 150 cases to test how accurately it could diagnose CIN lesions and cervical cancer.

The study found that the AI-based model was able to identify cervical precancerous lesions with high accuracy. In identifying lesions, the model had:

  • A sensitivity of 85% for CIN3 lesions, 86% for CIN2 lesions, and 87% for CIN1 lesions. Sensitivity is the percentage of people with a lesion who were correctly identified by the model as having a lesion.

  • A specificity of 73% for CIN3 lesions, 67% for CIN2 lesions, and 70% for CIN1 lesions. Specificity is the percentage of people who did not have a lesion and were correctly identified by the model as not having a lesion.

  • An area under the curve of 89% for the lesion area for CIN3 lesions and of 81% for both CIN2 and CIN1 lesions. The area under the curve indicates the overall accuracy of the model.

  • An accuracy of 95% for the number of lesions identified among CIN3 lesions, 93% for CIN2 lesions, and 97% for CIN1 lesions.

The model was also able to display a heatmap of the affected area with the highest acetic acid intensity, indicating where it was most likely for abnormal cells to be found, that corresponded with the actual biopsy location.

What does this mean for patients: For people who require a colposcopy after receiving abnormal Pap test results, an AI-based model may be helpful in accurately identifying cervical precancerous lesions, thus improving early detection and likelihood of curative therapy. This model could be especially useful in places where there may be fewer doctors trained in reading colposcopy results.

“Currently, there is no certification system for performing colposcopies in Japan, and the quality and interpretation of these examinations varies. Our study aimed to develop an artificial intelligence (AI)-based tool that reproduced colposcopy examination techniques of specialists to be used as a diagnostic aid by accurately identifying CIN lesions and guiding tissue sampling locations.”

—      lead study author Akihiko Ueda, MD
Kyoto University
Kyoto, Japan

Return to top

Liquid biopsy may help find common cancers before symptoms develop

Who does this study affect: People who have a moderate to high risk of cancer but no symptoms.

What did this study find: Results from the K-DETEK clinical trial in Vietnam have shown that a type of liquid biopsy called SPOT-MAS (Screening for the Presence Of Tumor by Methylation And Size) may be useful for detecting certain common cancers in people with no symptoms. The SPOT-MAS only looks for the 5 most common cancers in Vietnam: liver, breast, colorectal, stomach, and lung cancer. It is a type of liquid biopsy called a multiple cancer early detection test or MCED.

The researchers in this study wanted to see if the SPOT-MAS test could be used to successfully find early cases of cancer among Vietnamese people. This study includes 10,000 people aged 40 years or older with no symptoms of cancer but moderate to high risk of developing cancer. It was conducted in 13 large hospitals and 1 research institute in Vietnam. The participants were observed at 6 and 12 months. When the researchers analyzed the data, they had completed analyses for 2,795 study participants.   They found that the SPOT-MAS correctly detected cancer in 60% of cases, meaning that for every 100 positive tests, 60 of them will actually have cancer. In addition, the test was able to correctly identify the tumor’s location in 83.3% of cases. If SPOT-MAS detected cancer, then a patient received additional testing by doctors to confirm whether they really had cancer and then guide treatment decisions.

cancer screening tools, such as mammography and colonoscopy, usually only test for a single type of cancer and require separate appointments and procedures. In some parts of the world, this makes cancer screening difficult. Giving a single Blood test to screen people for several common types of cancer may be a convenient way to find cancer in people before they develop symptoms.

What does this mean for patients? The SPOT-MAS may be a helpful tool for initially screening people for common types of cancer, particularly in lower- and middle-income countries.

Common screening methods are often invasive, inaccessible, and involve separate procedures to screen individual cancer types. Affordable, accessible, noninvasive multicancer screening tests are needed for early detection, especially in a lower-middle income country like Vietnam. Our study provides clinical evidence for the applicability of the SPOT-MAS circulating tumor DNA-based assay as a complementary method in early cancer detection.”  

—senior study author Le Son Tran, PhD
Medical Genetics Institute
Ho Chi Minh City, Vietnam 

Return to top

Like what you’ve read here at cancer.Net? Sign up for our monthly Inside cancer.Net e-newsletter and follow cancer.Net on Facebook and Twitter for news about the latest in cancer care and treatment.



[ad_2]

cancer.net/blog/2023-07/2023-asco-breakthrough”>Source link

17th Edition of Oncology Award | 16-18 October 2023 | Paris, France



International Research Awards on Oncology and Cancer Research. It sounds like a prestigious award aimed at feting and recognizing the benefactions and achievements of experimenters and exploration associations in the field of oncology and cancer exploration. The eligibility criteria for the award is open to experimenters and scholars of all ethnicities, which is great for promoting diversity in the field. The appointees are estimated grounded on their once accomplishments, exploration excellence, and academic achievements, which is a good index of their impact in the field. Overall, the award appears to be an excellent way to admit and celebrate the achievements of experimenters working in the field of oncology and cancer exploration.

Theme: To celebrate researcher achievements and motivate them to continue on their path

More information – https://oncologyandcancerresearch.blogspot.com/

International Conference on Oncology and Cancer Research:- https://oncology.pencis.com/
Award Nomination link: https://x-i.me/oan
Abstract Submission link: https://x-i.me/srimonco

For Inquiries: oncology@pencis.com

#shorts #shortsvideo #breastcancer #prostatecancer #lungcancer #coloncancer #ovariancancer #pancreaticcancer #leukemia #lymphoma #OncologyConference #CancerResearch #OncologyAwards #CancerTreatment #OncologyCommunity #CancerCare #OncologyEducation #CancerSurvivorship #OncologyInnovation #CancerAwareness #OncologyLeadership #CancerPrevention #OncologyExcellence #CancerBreakthroughs #OncologyCollaboration #CancerAdvancements #OncologyImpact #CancerPatientsFirst #OncologyFuture #OncologyInspiration #CancerFighters #OncologyHeroes #CancerAwarenessMonth #OncologyProgress #CancerSolutions #OncologyExperts #CancerSurvivors #shorts #shortsvideo #cancerConference #OncologyConference #pencis #oncologyconference #CardioOnc #radonc #medonc #caxtx #GeriOnc #psyonc #oncorn #hsronc #camets #cancer #fuckcancer #cancersucks #breastcancerawareness #breastcancer #cancermemes #cancerousmemes #cancersurvivor #cancerawareness #cancerdemama #breastcancerawarenessmonth #cancerresearch #fightcancer #childhoodcancerawareness #beatcancer #childhoodcancer #cancerseason #breastcancersurvivor #cancerfree #cancerfighter #cancerous #fcancer #cancerwarrior #teamcancer #ovariancancer #americancancersociety #standuptocancer #cancerresearchuk #cancersupport #skincancer #cancermeme #cancer #feminismiscancer #curecancer #anticancer #cancerzodiac #prostatecancer #cancers #fucancer #pediatriccancer #cancerawareness #beatcancer #cancersucks #cancerresearch #cancerfighter #cancerwarrior #cancertreatment #cancersurvivor #cancerprevention #cancerawarenessmonth #cancerpatientsupport #breastcancer #prostatecancer #lungcancer #coloncancer #ovariancancer #pancreaticcancer #leukemia #lymphoma #melanoma #braincancer #childhoodcancer #cancerfree #oncology #cancercare #cancerdiagnosis #cancerribbon #cancerjourney

CONNECT HERE:-

Facebook : https://www.facebook.com/Conference-101261931798599
twitter :https://twitter.com/Samirabellil
pinterest : https://in.pinterest.com/OncologyandCancerResearch/
Blog :https://oncologyandcancerresearch.blogspot.com/
tumblr :https://www.tumblr.com/blog/view/cancer-researcher
instagram :https://www.instagram.com/oncology_researcher/
linkedin : https://www.linkedin.com/in/cathenna-malia-a20834219/

source

17th Edition of Oncology Summit | 16-18 October 2023 | Paris, France



The International Conference on Oncology and Cancer Research is an event that brings together researchers, healthcare professionals, and experts from the field of oncology and cancer research to discuss the latest developments and advancements in the field. The conference provides a platform for sharing new ideas, scientific knowledge, and research findings among the participants. The conference usually includes keynote speeches, plenary sessions, oral presentations, poster sessions, and workshops. The conference topics may include but are not limited to, the following areas of cancer research: Basic cancer research, Clinical trials and studies, Cancer prevention and early detection, Cancer diagnosis and treatment, Cancer therapies and new treatments, Cancer epidemiology and statistics, Cancer informatics and technology, Cancer rehabilitation and palliative care, Cancer policy and advocacy. The International Conference on Oncology and Cancer Research is an opportunity for professionals from various backgrounds to come together and collaborate on ways to improve the diagnosis, treatment, and overall management of cancer.

More information – https://oncologyandcancerresearch.blogspot.com/

International Conference on Oncology and Cancer Research:- https://oncology.pencis.com/
Award Nomination link: https://x-i.me/oan
Abstract Submission link: https://x-i.me/srimonco

For Inquiries: oncology@pencis.com

#shorts #shortsvideo #breastcancer #prostatecancer #lungcancer #coloncancer #ovariancancer #pancreaticcancer #leukemia #lymphoma #OncologyConference #CancerResearch #OncologyAwards #CancerTreatment #OncologyCommunity #CancerCare #OncologyEducation #CancerSurvivorship #OncologyInnovation #CancerAwareness #OncologyLeadership #CancerPrevention #OncologyExcellence #CancerBreakthroughs #OncologyCollaboration #CancerAdvancements #OncologyImpact #CancerPatientsFirst #OncologyFuture #OncologyInspiration #CancerFighters #OncologyHeroes #CancerAwarenessMonth #OncologyProgress #CancerSolutions #OncologyExperts #CancerSurvivors #shorts #shortsvideo #cancerConference #OncologyConference #pencis #oncologyconference #CardioOnc #radonc #medonc #caxtx #GeriOnc #psyonc #oncorn #hsronc #camets #cancer #fuckcancer #cancersucks #breastcancerawareness #breastcancer #cancermemes #cancerousmemes #cancersurvivor #cancerawareness #cancerdemama #breastcancerawarenessmonth #cancerresearch #fightcancer #childhoodcancerawareness #beatcancer #childhoodcancer #cancerseason #breastcancersurvivor #cancerfree #cancerfighter #cancerous #fcancer #cancerwarrior #teamcancer #ovariancancer #americancancersociety #standuptocancer #cancerresearchuk #cancersupport #skincancer #cancermeme #cancer #feminismiscancer #curecancer #anticancer #cancerzodiac #prostatecancer #cancers #fucancer #pediatriccancer #cancerawareness #beatcancer #cancersucks #cancerresearch #cancerfighter #cancerwarrior #cancertreatment #cancersurvivor #cancerprevention #cancerawarenessmonth #cancerpatientsupport #breastcancer #prostatecancer #lungcancer #coloncancer #ovariancancer #pancreaticcancer #leukemia #lymphoma #melanoma #braincancer #childhoodcancer #cancerfree #oncology #cancercare #cancerdiagnosis #cancerribbon #cancerjourney

CONNECT HERE:-

Facebook : https://www.facebook.com/Conference-101261931798599
twitter :https://twitter.com/Samirabellil
pinterest : https://in.pinterest.com/OncologyandCancerResearch/
Blog :https://oncologyandcancerresearch.blogspot.com/
tumblr :https://www.tumblr.com/blog/view/cancer-researcher
instagram :https://www.instagram.com/oncology_researcher/
linkedin : https://www.linkedin.com/in/cathenna-malia-a20834219/

source

New immunotherapy drug shows promise as cancer treatment, research suggests

[ad_1]

oncology.pencis.com/” style=”clear: right; float: right; margin-bottom: 1em; margin-left: 1em;”>

oncology.pencis.com/”>A new class of Conference-registration-euro/”>immunotherapy could offer hope to cancer patients who do not respond to existing treatments, Research suggests.

oncology.pencis.com/”>The study found the drug, called MOv18 IgE, shrank a tumour in a patient with ovarian cancer and reported that it was well tolerated in patients.

oncology.pencis.com/”>The scientists suggest their findings could pave the way for a completely new type of anti-cancer drug for people with Award-call-for-profile/”>Chemotherapy-resistant cancers.

oncology.pencis.com/”>The study by researchers from King’s College London and Guy’s and St Thomas’ NHS Foundation Trust, and funded by cancer Research UK, tested whether a type of antibody called IgE could be used to treat human cancer.oncology.pencis.com/”/>

oncology.pencis.com/”>The results pave the way to development of an entirely new class of anti-cancer drug for people with Award-call-for-profile/”>Chemotherapy-resistant cancers

                                                         oncology.pencis.com/”>Professor James Spicer, King’s College London

oncology.pencis.com/”>Conference-registration-euro/”>immunotherapy works by stimulating the body’s natural defence system to attack cancer.

oncology.pencis.com/”>Existing antibody drugs used in cancer belong to an antibody type called IgG, but IgE antibodies have not been tested in humans before.

oncology.pencis.com/”>IgE antibodies evolved to target parasites like worms and flukes, and IgG antibodies are involved in attacking bacteria and viruses in the body.

oncology.pencis.com/”>Lead author on the study, Professor James Spicer, professor of experimental cancer medicine at King’s College London and Consultant in Medical oncology at Guy’s and St Thomas’ NHS Foundation Trust (GSTT), said: “IgE is a completely new form of antibody therapy which has shown great promise in this Phase I trial.

oncology.pencis.com/”>“Our findings show that the drug was well tolerated in patients and shrunk a cancerous tumour in a patient with ovarian cancer.

oncology.pencis.com/”>“The results pave the way to development of an entirely new class of anti-cancer drug for people with Award-call-for-profile/”>Chemotherapy-resistant cancers.oncology.pencis.com/”>“The immunology expertise in King’s College London laboratories allowed us to undertake this trial of a completely new form of antibody therapy.”oncology.pencis.com/”/>

oncology.pencis.com/”>Conference-registration-euro/”>immunotherapy has shown enormous potential recently but there are still people with cancer who do not respond to conventional therapy
                                                              oncology.pencis.com/”>Professor Sophia Karagiannis, King’s College London

oncology.pencis.com/”>Co-author Sophia Karagiannis, professor of translational cancer immunology and Conference-registration-euro/”>immunotherapy at King’s College London, said: “Conference-registration-euro/”>immunotherapy has shown enormous potential recently but there are still people with cancer who do not respond to conventional therapy.

oncology.pencis.com/”>“This trial builds on our previous work into the biology of IgE, including experiments in the laboratory suggesting that IgE could be an effective treatment that can offer additional benefits to complement those of established IgG antibodies in the clinic.

oncology.pencis.com/”>“While we are still in the early stage of trials, our next steps will be to evaluate IgE in larger and different groups of patients and to continue studying how IgE antibodies are able to wake up the patient’s immune system to fight different cancers.”

#prostatecancer #lungcancer #coloncancer #ovariancancer #pancreaticcancer #leukemia #Conference-registration-usd/”>Lymphoma #OncologyConference #CancerResearch #OncologyAwards #CancerTreatment #OncologyCommunity #CancerCare #OncologyEducation #CancerSurvivorship #OncologyInnovation #CancerAwareness #OncologyLeadership #CancerPrevention #OncologyExcellence #CancerBreakthroughs #OncologyCollaboration #CancerAdvancements #OncologyImpact #CancerPatientsFirst #OncologyFuture #OncologyInspiration #CancerFighters #OncologyHeroes #CancerAwarenessMonth #OncologyProgress #CancerSolutions #OncologyExperts #CancerSurvivors #shorts #shortsvideo #cancerConference #OncologyConference #pencis #oncologyconference #CardioOnc #radonc #medonc #caxtx #GeriOnc #psyonc #oncorn #hsronc #camets #cancer #fuckcancer #cancersucks #breastcancerawareness #breastcancer #cancermemes #cancerousmemes #cancersurvivor #cancerawareness #cancerdemama #breastcancerawarenessmonth #cancerresearch #fightcancer #childhoodcancerawareness #beatcancer #childhoodcancer #cancerseason #breastcancersurvivor #cancerfree #cancerfighter #cancerous #fcancer #cancerwarrior #teamcancer #ovariancancer #americancancersociety #standuptocancer #cancerresearchuk #cancersupport #skincancer #cancermeme #cancer #feminismiscancer #curecancer #anticancer #cancerzodiac #prostatecancer #cancers #fucancer #pediatriccancer #cancerawareness #beatcancer #cancersucks #cancerresearch #cancerfighter #cancerwarrior #cancertreatment #cancersurvivor #cancerprevention #cancerawarenessmonth #cancerpatientsupport #breastcancer #prostatecancer #lungcancer #coloncancer #ovariancancer #pancreaticcancer #leukemia #Conference-registration-usd/”>Lymphoma #melanoma #braincancer #childhoodcancer #cancerfree #oncology #cancercare #cancerdiagnosis #cancerribbon #cancerjourney

[ad_2]

Conference-registration-euro/”>immunotherapy-drug-shows-promise-as.html”>Source link

2023 Healing Hearts Family Bereavement Camp

[ad_1]

cancerCare’s Annual Healing Hearts Family Bereavement Camp Offers a Sea of Support

alt text

This July, families who recently lost a loved one to cancer came together at Memorytown USA in Mount Pocono, PA for cancerCare’s free annual Healing Hearts Family Bereavement Camp. 19 families and close to 40 children and adolescents, ages 4-17, attended this year’s camp from July 14-16.

After families arrived on Friday night, they had the opportunity to gather for dinner, play games, make s’mores and dance to music, courtesy of DJ Angelo. Returning children, once again, sat together at their own table, and made more room for the larger number of children this year. “Seeing that was just amazing because instead of one table, it was two tables,” shared Kathy Nugent, cancerCare’s Senior Director of Regional Programs.

alt text

This year’s camp theme was the ocean, and families made sea-themed memory jars and collages about their loved ones on Saturday. Adults gathered in support groups while children and adolescents gathered in age-specific groups.

Younger children were read “Always Remember,” by Cece Meng, donated by the Light One Little Candle Foundation. They were also taught a dance by cancerCare social worker Nikki Molfetas and decorated canvas bags and memory stones. Meanwhile, older children and teens wrote lyrics to “Hope Floats,” a song composed by Sarah Paul, cancerCare’s Director of Clinical Programs.

The families participated in horseback riding at Mountain Creek Riding Stables, fishing, crafts, lawn games and water activities, which included a sea turtle-themed sprinkler system. They also gathered for a memorial service where the children’s’ groups performed and they were able to honor their loved ones.

alt text

Saturday night, they also participated in karaoke. But “Karaoke was not just karaoke,” noted Cecilia Kuepper, cancerCare‘s Healing Hearts Program Coordinator. “It’s those connections that you make and how the kids are just being kids in that moment.”

On Sunday, adults attended a resilience panel, where people who had experienced similar losses gave the attendees hope and inspiration. “It’s really inspirational for them to listen to these stories because it gives them hope that their children will be okay and that they will be okay,” said Kathy. “They see a life moving forward.”

The children had the opportunity to learn and speak about the different emotions they were experiencing with cancerCare social workers. Younger children released their emotions with kickboxing taught by Kat Morano, cancerCare‘s Education Outreach Coordinator, while older children participated in meditation guided by Nikki. They also built, decorated and flew sea turtle kites.

The weekend ended with a closing ceremony where attendees were invited to share their thoughts and gratitude and received gifts including sea turtle-themed wind chimes and bracelets.

“Having the interactions with other families experiencing loss had a healing effect on my own family,” one attendee shared. “We left camp feeling hope, not hopeless.”

One parent shared, “The kids are more open to talking to us about our loss and how they feel since the camp. I’m glad the camp helped normalize it for us and our children.”

“All the families expressed their gratitude and were so happy to have met others who are experiencing similar loss,” Kathy shared. “There were lots of laughs and tears but everyone went home feeling uplifted.”

alt text

The Healing Hearts Family Bereavement Camp would not be possible without our volunteers, partners and supporters. Special thanks to Eisai, our primary sponsor, as well as our other supporters, including the Lillian Schenck Foundation, Valley Hospital Foundation, DeAnna Stark Pasciuto Memorial Fund – Northern New Jersey Community Foundation and Genmab. We would like to thank the Giving Doll Foundation for the donation of dolls and the Light One Little Candle Foundation for the donation of books for the children. We would also like to thank Memorytown USA for providing excellent services and meals to our families, staff and volunteers as well as Mountain Creek Riding Stables for hosting horseback riding.

Like all of cancerCare‘s services, the Healing Hearts Family Bereavement Camp is made available to families completely free of charge. Please consider making a contribution to help support families coping with the loss of a loved one. You can also contact Kathy Nugent at 201-301-6809 or knugent@cancercare.org should you wish to make a charitable contribution.



[ad_2]

Source link

Enhertu Shows Promise for Several Types of HER2-Positive Cancer

[ad_1]

oncology.pencis.com/” target=”_blank”>

oncology.pencis.com/” target=”_blank”>

oncology.pencis.com/” target=”_blank”>

oncology.pencis.com/” target=”_blank”>The antibody-drug conjugate Enhertu (trastuzumab deruxtecan), which is currently approved for advanced breast, lung and stomach cancer, is also effective for people with several other types of tumors that express HER2, according to Research presented at the 2023 American Society of Clinical oncology (ASCO) Annual Meeting.

oncology.pencis.com/” target=”_blank”>In the Phase II DESTINY-PanTumor02 study, overall response rates were 45% for ovarian cancer, 50% for cervical cancer and 58% for endometrial but only reached 4% for hard-to-treat pancreatic cancer. Rates were higher for tumors with stronger HER2 expression. A related study saw a 38% response rate for advanced colorectal cancer.

oncology.pencis.com/” target=”_blank”>“HER2 is present in many cancer types, such as breast, gastric, lung, gynecologic and urothelial cancers, and patients with HER2-expressing, hard-to-treat cancers need new treatment options,” lead investigator Funda Meric-Bernstam, MD, of the University of Texas MD Anderson cancer Center, said in an ASCO press release.

oncology.pencis.com/” target=”_blank”>“These results advance our clinical understanding of HER2 expression, reaffirm HER2 as an actionable biomarker across a broad range of tumor types and show that trastuzumab deruxtecan could potentially provide a new treatment option for patients with advanced disease across these tumors.”

oncology.pencis.com/” target=”_blank”>Enhertu, from Daiichi Sankyo and AstraZeneca, is an antibody-drug conjugate, a new type of treatment that uses antibodies to deliver toxic Award-call-for-profile/”>Chemotherapy drugs directly to tumors. Enhertu combines the monoclonal antibody trastuzumab (Herceptin), which targets HER2, with a topoisomerase inhibitor as a payload. Tumors that strongly express HER2—a receptor for a protein that promotes cell growth—are classified as HER2-positive.

oncology.pencis.com/” target=”_blank”>The Food and Drug Administration initially granted accelerated approval of Enhertu for the treatment of inoperable or metastatic HER2-positive breast cancer in 2019. At last year’s ASCO meeting, researchers reported that Enhertu also works well for breast tumors with low HER2 expression, leading to approval for that indication and expanding the eligible patient population. Enhertu is also approved for HER2-positive non-small-cell lung cancer and gastric or gastroesophageal junction cancer. This suggests that people with other types of HER2-expressing tumors could benefit as well.

oncology.pencis.com/” target=”_blank”>The open-label DESTINY-PanTumor02 trial (NCT04482309) enrolled 267 previously treated patients with HER2-expressing locally advanced or metastatic biliary tract, bladder (urothelial), cervical, endometrial, ovarian, pancreatic or other tumors. They either had progressed after at least one systemic treatment or had no available treatment options. Seventy-five patients had tumors classified as IHC 3+ (high HER2 expression), while 125 were classified as IHC 2+ (moderate HER2 expression). The participants received Enhertu at a dose of 5.4 milligrams per kilogram by intravenous infusion every three weeks.

oncology.pencis.com/” target=”_blank”>After a median follow-up period of 9.7 months, objective response rates, indicating tumor shrinkage or remission, varied widely across cancer types and were generally better for tumors with higher HER2 expression:

  • oncology.pencis.com/” target=”_blank”>Endometrial cancer: 58% overall, 85% for IHC 3+, 47% for IHC 2+
  • oncology.pencis.com/” target=”_blank”>Cervical cancer: 50% overall, 75% for IHC 3+, 40% for IHC 2+
  • oncology.pencis.com/” target=”_blank”>Ovarian cancer: 45% overall, 63% for IHC 3+, 37% for IHC 2+
  • oncology.pencis.com/” target=”_blank”>Bladder cancer: 39% overall, 56% for IHC 3+, 35% for IHC 2+
  • oncology.pencis.com/” target=”_blank”>Biliary tract cancer: 22% overall, 56% for IHC 3+, 0% for IHC 2+
  • oncology.pencis.com/” target=”_blank”>Pancreatic cancer: 4% overall, 0% for IHC 3+, 5% for IHC 2+
  • oncology.pencis.com/” target=”_blank”>Other tumor types: 30% overall, 44% for IHC 3+, 19% for IHC 2+.

oncology.pencis.com/” target=”_blank”>Across all tumor types, the median duration of response was 11.8 months, rising to 22.1 months for people with IHC 3+ tumors.

oncology.pencis.com/” target=”_blank”>In a related presentation, researchers reported results from the Phase II DESTINY-CRC02 trial (NCT04744831), showing an overall response rate of 38% for people with locally advanced or metastatic colorectal cancer who were treated with the optimal 5.4 mg/kg dose. Here, too, the response rate was higher for patients with IHC 3+ tumors (47%) versus IHC 2+ tumors (6%). The median duration of response was 5.5 months, the median progression-free survival time was 5.8 months and the median overall survival time was 13.4 months.

oncology.pencis.com/” target=”_blank”>Treatment with Enhertu was generally safe, though side effects were common. The most frequently reported severe (Grade 3 or higher) treatment-related adverse events in DESTINY PanTumor02 were white Blood cell deficiency (19%), Award-nomination/”>Anemia (9%), fatigue (6%) and platelet deficiency (5%). Twenty people (8%) developed treatment-related interstitial lung disease or pneumonitis (lung inflammation). About 12% of participants stopped treatment due to side effects.

oncology.pencis.com/” target=”_blank”>“This study provides data for an unmet need for patients who have exhausted standard therapeutic options with tumors that overexpress HER2 for which no drug is yet approved,” said ASCO expert Bradley McGregor, MD, of the Dana-Farber cancer Institute. “While additional follow-up is needed, there is robust activity across multiple HER2-expressing tumors with over 50% response rate in those with the highest levels of HER2 expression coupled with an encouraging safety profile. Trastuzumab deruxtecan could provide a new treatment option for these patients.”

oncology.pencis.com/” target=”_blank”>Click here to ready the DESTINY-PanTumor02 and DESTINY-CRC02 study abstracts.
Click here for more reports from ASCO 2023.
Click here to learn more about pancancer treatment.


    oncology.pencis.com/” target=”_blank”>Read More About:

    oncology.pencis.com/” target=”_blank”>

  • #antibody-drug conjugate
  •  

  • #biliary tract cancer
  •  

  • #bladder cancer
  •  

  • #cancer treatment
  •  

  • #cervical cancer
  •  

  • #colon cancer
  •  

  • #colorectal cancer
  •  

  • #endometrial cancer
  •  

  • #Enhertu
  •  

  • #ovarian cancer
  •  

  • #pancreatic cancer
  •  

  • #targeted therapy

[ad_2]

Source link

Unraveling the role of core promoter variation in triple-negative breast cancer: Study

[ad_1]

Unraveling the role of core promoter variation in triple-negative breast <a href=cancer: A breakthrough study” title=”Variants in core promoter interfere with the cis–trans interaction and the organization of transcriptional initiation complex, leading to increased or decreased transcription initiation. Green line represents wild-type and red line represents mutant. Credit: Genes & Diseases” width=”357″ height=”271″/>
Variants in core promoter interfere with the cis–trans interaction and the organization of transcriptional initiation complex, leading to increased or decreased transcription initiation. Green line represents wild-type and red line represents mutant. Credit: Genes & Diseases

TNBC is a particularly aggressive subtype of breast cancer, characterized by the absence of three key receptors: estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). Approximately 10–20% of all breast cancers are TNBC. TNBC patients face a poorer prognosis due to the lack of specific drug targets. Therefore, the discovery of new factors influencing the development and progression of TNBC is crucial for improving patient outcomes.

A study published in Genes & Diseases centered on the core promoter, a DNA region surrounding the transcription start site (TSS), for the potential roles of genetic variation in core promoter in abnormal gene expression in TNBC. Core promoters contain multiple highly conserved cis-motifs interacting with different transcriptional factors like RNA polymerase II, TFIIB, and TFIID.

This interaction forms the transcription initiation complex to regulate transcriptional initiation. Genetic variation in the core promoter sequences could interfere with this interaction therefore the proper organization of the transcriptional initiation complex, causing altered transcription initiation and pathological consequences.

Researchers hypothesized that core promoter in TNBC could be highly mutable in contributing to its abnormal gene expression. To test their theory, they analyzed the genomes of 279 TNBC patients using a method called Exome-based Variant Detection in Core-promoters (EVDC).

After filtering out normal genomic polymorphisms, researchers discovered a staggering 19,427 recurrent somatic variants and 1,694 recurrent germline variants in the core promoters of various genes, many of which are known to be oncogenes and tumor suppressors.

The analysis of RNA-seq data from breast cancer revealed altered gene expression in hundreds of these affected genes, providing substantial evidence that core promoter variation could significantly influence gene expression. The researchers further compared these findings with core promoter variation data from 610 unclassified breast cancers. Interestingly, the core promoter variants in TNBC were highly TNBC-specific, suggesting that these variations could contribute significantly to the unique characteristics of TNBC.

This study makes a clear case that the core promoter is mutable and can significantly contribute to the development of cancer, in particular TNBC. While it sheds light on an entirely new aspect of cancer research, there is still much to uncover.

The complex, dynamic nature of gene expression and the variety of mechanisms that can influence it, including epigenetic modification and variation in distal regulatory regions, means that this is just the beginning. The researchers concluded that core promoter variation could provide a new paradigm for studying the mechanisms behind abnormal gene expression in cancer.

While this study focused on TNBC, future research could potentially uncover similar roles of core promoter variation in other types of cancer, leading to even broader applications for cancer detection and treatment.

More information:
Teng Huang et al, Etiological roles of core promoter variation in triple-negative breast cancer, Genes & Diseases (2022). DOI: 10.1016/j.gendis.2022.01.003

Provided by
Chongqing Medical University

Citation:
Unraveling the role of core promoter variation in triple-negative breast cancer: Study (2023, July 25)
retrieved 26 July 2023
from https://medicalxpress.com/news/2023-07-unraveling-role-core-variation-triple-negative.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.



[ad_2]

Source link

To manage and reduce the risk of lymphedema, cancer patients are often advised to:



Practice gentle exercise and physical activity to promote lymphatic flow.
Avoid constrictive clothing or jewelry on the affected limb.
Keep the affected limb elevated when resting.
Avoid extreme temperatures (hot baths, saunas) that could worsen swelling.
Maintain good skin hygiene and prevent cuts, scrapes, or burns on the affected limb.
Consult with a certified lymphedema therapist who can provide specialized treatments such as manual lymphatic drainage and compression therapy.

More information – https://oncologyandcancerresearch.blogspot.com/

International Conference on Oncology and Cancer Research:- https://oncology.pencis.com/
Award Nomination link: https://x-i.me/oan
Abstract Submission link: https://x-i.me/srimonco

For Inquiries: oncology@pencis.com

 #shorts #shortsvideo  #breastcancer #prostatecancer #lungcancer #coloncancer #ovariancancer #pancreaticcancer #leukemia #lymphoma     #OncologyConference #CancerResearch #OncologyAwards #CancerTreatment #OncologyCommunity #CancerCare #OncologyEducation #CancerSurvivorship #OncologyInnovation #CancerAwareness #OncologyLeadership #CancerPrevention #OncologyExcellence #CancerBreakthroughs #OncologyCollaboration #CancerAdvancements #OncologyImpact #CancerPatientsFirst #OncologyFuture #OncologyInspiration #CancerFighters #OncologyHeroes #CancerAwarenessMonth  #OncologyProgress #CancerSolutions #OncologyExperts #CancerSurvivors  #shorts #shortsvideo #cancerConference #OncologyConference #pencis #oncologyconference  #CardioOnc  #radonc #medonc #caxtx #GeriOnc #psyonc #oncorn #hsronc #camets #cancer #fuckcancer #cancersucks #breastcancerawareness #breastcancer #cancermemes #cancerousmemes #cancersurvivor #cancerawareness #cancerdemama #breastcancerawarenessmonth #cancerresearch #fightcancer #childhoodcancerawareness #beatcancer #childhoodcancer #cancerseason #breastcancersurvivor #cancerfree #cancerfighter #cancerous #fcancer #cancerwarrior #teamcancer #ovariancancer #americancancersociety #standuptocancer #cancerresearchuk #cancersupport #skincancer #cancermeme #cancer #feminismiscancer #curecancer #anticancer #cancerzodiac #prostatecancer #cancers #fucancer #pediatriccancer  #cancerawareness #beatcancer #cancersucks #cancerresearch #cancerfighter #cancerwarrior #cancertreatment #cancersurvivor #cancerprevention #cancerawarenessmonth #cancerpatientsupport #breastcancer #prostatecancer #lungcancer #coloncancer #ovariancancer #pancreaticcancer #leukemia #lymphoma #melanoma #braincancer #childhoodcancer #cancerfree #oncology #cancercare #cancerdiagnosis #cancerribbon #cancerjourney

CONNECT HERE:-

Facebook  : https://www.facebook.com/Conference-101261931798599
twitter        :https://twitter.com/Samirabellil
pinterest    : https://in.pinterest.com/OncologyandCancerResearch/
Blog          :https://oncologyandcancerresearch.blogspot.com/
tumblr       :https://www.tumblr.com/blog/view/cancer-researcher
instagram :https://www.instagram.com/oncology_researcher/
linkedin     : https://www.linkedin.com/in/cathenna-malia-a20834219/

source